RESOLVE-1, a Phase III Trial of Lenabasum for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Lenabasum is an oral, non-immunosuppressive, cannabinoid Type 2 receptor agonist that activates resolution of innate immune responses.1 In animal models of bleomycin-induced skin and lung fibrosis, lenabasum reduced inflammation and fibrosis